Literature DB >> 10366120

Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis.

C Salvarani1, G G Hunder.   

Abstract

OBJECTIVE: To define musculoskeletal manifestations occurring in a population-based cohort of patients with giant cell (temporal) arteritis (GCA).
METHODS: The records of 128 patients with GCA diagnosed over a 42-year-period (1950-1991) in Olmsted County, MN, were reviewed for the presence and type of musculoskeletal manifestations, their relationship to the onset and course of GCA, and their response to treatment.
RESULTS: Fifty-three patients (41%) developed polymyalgia rheumatica: 23 before, 17 concurrently with, and 13 after the diagnosis of GCA. Thirty patients (23%) developed 1 or more peripheral musculoskeletal manifestations. These included peripheral synovitis in 23 patients (6 of whom fulfilled criteria for rheumatoid arthritis), distal extremity swelling with pitting edema in 13, distal swelling without pitting in 5, tenosynovitis in 6, and carpal tunnel syndrome in 2. Fifty-seven episodes of peripheral manifestations occurred in the 30 patients at different times during the course of GCA. In most, the onset of PMR and peripheral manifestations was within 2 years of the diagnosis of GCA.
CONCLUSION: Musculoskeletal symptoms in GCA are common and varied. Most appear linked temporally to the underlying GCA, indicating that the nature of this illness and its clinical expression are broader than often considered.

Entities:  

Mesh:

Year:  1999        PMID: 10366120     DOI: 10.1002/1529-0131(199906)42:6<1259::AID-ANR24>3.0.CO;2-I

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

Review 1.  Perspective on future therapy of vasculitis.

Authors:  D T Boumpas; H D Kritikos; N G Daskalakis
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

Review 2.  Giant cell arteritis, polymyalgia rheumatica, and late-onset rheumatoid arthritis: Can they be components of a single disease process in elderly patients?

Authors:  Cengiz Korkmaz; Pınar Yıldız
Journal:  Eur J Rheumatol       Date:  2017-02-24

Review 3.  [Polymyalgia rheumatica: myalgic syndrome or occult vasculitis?].

Authors:  B Hellmich; W L Gross
Journal:  Internist (Berl)       Date:  2005-11       Impact factor: 0.743

Review 4.  Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.

Authors:  Jean Schmidt; Kenneth J Warrington
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 5.  Spondyloarthritis with onset after age 45.

Authors:  Ignazio Olivieri; Salvatore D'Angelo; Angela Padula; Pietro Leccese; Carlo Palazzi
Journal:  Curr Rheumatol Rep       Date:  2013-12       Impact factor: 4.592

6.  Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis.

Authors:  M Cutolo; C M Montecucco; L Cavagna; R Caporali; S Capellino; P Montagna; L Fazzuoli; B Villaggio; B Seriolo; A Sulli
Journal:  Ann Rheum Dis       Date:  2006-04-27       Impact factor: 19.103

Review 7.  Diagnosis, differential diagnosis and treatment of polymyalgia rheumatica.

Authors:  Thomas Nothnagl; Burkhard F Leeb
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 8.  Spectrum of giant cell vasculitis.

Authors:  N Mohan; G Kerr
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

9.  Pattern of Young and Old Onset Rheumatoid Arthritis (YORA and EORA) Among a Group of Egyptian Patients with Rheumatoid Arthritis.

Authors:  Abdou S El-Labban; Hanaa A S Abo Omar; Rawhya R El-Shereif; Fatma Ali; Tarek M El-Mansoury
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2010-05-20

10.  Clinical, radiological, and biochemical characteristics in patients with diseases mimicking polymyalgia rheumatica.

Authors:  Hidekatsu Yanai; Hiroshi Yoshida; Norio Tada
Journal:  Clin Interv Aging       Date:  2009-10-12       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.